First genetic map of malaria drug plant could increase crop yields, study says

NewsGuard 100/100 Score

The first genetic map of the plant Artemisia annua, which could "help scientists develop the species into a high-yielding crop" to fight malaria, was published in a study in the journal Science on Thursday, Reuters reports (Kelland, 1/14).

The plant is used to produce artemisinin, a "potent weapon" in malaria treatments, according to VOA News, which notes that "supplies of the medication are limited because" Artemisia annua is "a low-yielding wild plant." The news service continues, "As a result, artemisinin costs ten times more than other anti-malarials, so it is used sparingly in combination with other drugs to boost their effectiveness" (Berman, 1/14).

The new genetic map, "drawn up a team led by Dianna Bowles and Ian Graham, of the University of York, will help to alleviate this shortage by accelerating breeding programmes for higher-yielding crops," London's Times reports. The research was funded by two grants worth $26 million from the Bill & Melinda Gates Foundation, according to the Times (Henderson, 1/15).

Bowles said, "The map is already proving to be an essential tool for us. With our new understanding of Artemisia genetics, we can produce improved, non-GM varieties ... much faster than would otherwise be possible," Reuters reports (1/14). Graham said the scientists' goal "is to have hybrid seeds that can be released to farmers in the developing world by 2011 or 2012. With a year lag for planting, this would have an impact on supply in 2012 or 2013," BBC writes (Walton, 1/14).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Single dose of malaria monoclonal antibody 77% effective in children, trial in Mali shows